Who is sponsoring NCT00102947?

NCT00102947 is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What condition does NCT00102947 study?

NCT00102947 studies Soft Tissue Infections.

What drugs are being tested in NCT00102947?

Interventions: daptomycin (up to 14 days).

What is the status of NCT00102947?

NCT00102947 is currently TERMINATED.

Last reviewed 2016-07-22 · How we verify

An Open Label Phase 4 Trial to Further Evaluate the Pharmacokinetic Profile of Intravenous Daptomycin, and a Comparison of the Safety and Efficacy of Daptomycin Versus Comparator in the Treatment of Adult Patients With Renal Impairment and Complicated Skin and Skin Structure Infections Due, at Least in Part, to Gram-positive Bacteria

NCT00102947 Phase 4 TERMINATED

This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.

Details

Lead sponsor	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 4
Status	TERMINATED
Enrolment	72
Start date	2005-01
Completion	2006-11

Conditions

Soft Tissue Infections

Interventions

daptomycin (up to 14 days)

Primary outcomes

To obtain additional pharmacokinetic data (on dosing days) on intravenous daptomycin in patients with complicated skin and skin structure infections and renal impairment

Countries

United States